Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising
as the industry has posted a 19.9% gain over the past six months, beating the S&P 500 by 9.1 percentage points.
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 4, 2026.
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
The global healthcare landscape shifted decisively on December 16, 2025, with the public market return of Medline Industries (Nasdaq: MDLN). After four years under the stewardship of a private equity consortium—and decades of private family ownership before that—the medical supply titan has reclaimed its status as a public entity in the largest U.S. initial public [...]
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at health insurance providers stocks, starting with Cencora (NYSE:COR).
CRANFORD, NJ — As the 2025 calendar year draws to a close, Citius Oncology, Inc. (Nasdaq: CTOR) has reached a pivotal juncture in its corporate evolution. Following the release of its SEC 10-K filing for the fiscal year ended September 30, 2025, the company has officially shed its "development-stage" label, entering
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
In a stunning return to the public stage, Medline Industries (Nasdaq: MDLN) successfully executed the largest initial public offering (IPO) in the United States since 2021, pricing its shares at the top of its range and witnessing a massive first-day "pop" that has sent ripples through the financial world. The
Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset management firm.
The global economy is witnessing a transformative surge in data center investment and growth, propelled primarily by the insatiable demands of Artificial Intelligence (AI), the ever-expanding reach of cloud computing, and pervasive digital transformation initiatives. This unprecedented expansion is not merely a technological phenomenon but a potent economic indicator, channeling
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Shares of healthcare distributor Cencora (NYSE:COR)
fell 4.3% in the afternoon session after analysts downgraded the company's stock to a "hold" rating from a "buy" a few days prior. This downgrade added to a negative trend for the stock, which had already fallen over the previous five trading sessions. The downward pressure from the new rating appeared to weigh on investor sentiment. The stock's performance reflected the market's reaction to the lowered expectations from the analyst firm.
Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped returns as the industry’s six-month gain of 11.6% has lagged the S&P 500’s 16.3% climb.
Cencora’s third quarter saw a positive market response, as the company delivered revenue and non-GAAP earnings that exceeded Wall Street expectations. Management pointed to strong growth in its U.S. Healthcare Solutions segment and the contribution of specialty pharmaceuticals as key drivers. CEO Robert Mauch emphasized that investments in areas like specialty distribution and recent acquisitions, such as Retina Consultants of America, enhanced the company’s value to both pharmaceutical manufacturers and healthcare providers. The segment’s operating income growth, driven by volume increases and higher-margin specialty products, was a highlight for the quarter.
Healthcare distributor Cencora (NYSE:COR) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 5.9% year on year to $83.73 billion. Its non-GAAP profit of $3.84 per share was 1.4% above analysts’ consensus estimates.
Healthcare distributor Cencora (NYSE:COR) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.9% year on year to $83.73 billion. Its non-GAAP profit of $3.84 per share was 1.4% above analysts’ consensus estimates.
Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $(1.75) for the September quarter of fiscal 2025, compared to $0.02 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 15.0 percent to $3.84 in the fiscal fourth quarter. For fiscal year 2025, diluted GAAP EPS increased 5.7 percent to $7.96. For fiscal year 2025, adjusted diluted EPS increased 16.3 percent to $16.00.
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.
